Overall rank by patents
#44,130
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 8 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA).
The verdict
Xact holds 6 US patents across 8 technology areas, rank #44,130 of 50,000 tracked assignees.
Xact Laboratories, Llc has been granted 6 US utility patents between 2022 and 2025, placing Xact Laboratories, Llc at rank #44,130 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.2 claims per patent with primary concentration in G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA). As a US Corporation, Xact Laboratories, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Xact sits between Xvivo Perfusion AB (6 patents, rank #44,126) and Xeeva, Inc. (6 patents, rank #44,134) - the closest US assignees by grant volume. The composite Innovation Score of 44.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Xact Laboratories, Llc's 12.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Xact Laboratories, Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
XVIVO PERFUSION AB
6 patents
XYPHOS BIOSCIENCES INC.
6 patents
XYZ ENERGY GROUP, LLC
6 patents
XYZ INTERACTIVE TECHNOLOGIES INC.
6 patents
Xactiv, Inc.
6 patents
Xcelemor, Inc.
6 patents
Xciel, Inc.
6 patents
Xeeva, Inc.
6 patents
Xact Laboratories, LLC
6 patents
What this shows Xact holds 6 patents at rank #44,130, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,130 in granted patent volume.
Other assignees with the most granted patents in Xact's primary technology class.
Xact's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
44 Top 27% higher than 73% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 4 | 66.7% |
| 2025 | 2 | 33.3% |
Top 8 of 8 technology areas
Overall rank by patents
#44,130
Across all tracked assignees
44.0 out of 100
How to use this portfolio
Xact's 6 grants land it in the top 27% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.